 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
Cat B 680 FAST |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Part #
|
 |
Agent Description
|
|
|
11112 |
|
Cat B 680 FAST including 1 vial, 10 doses (based on a 20-25 g mouse)- Fluorescence agent specifically activated by cathepsin B proteinases (Cat B). Optically silent in the unactivated state, becoming highly fluorescent when activated. |
|
|
Cat B 680 FASTTM is a member of a family of activatable fluorescent imaging agents comprising a novel architecture, termed F.A.S.T. (Fluorescent Activatable Sensor Technology) that confers an improved pharmacokinetic profile with a broader range of early imaging timepoints. This architecture also offers higher target specific signal with reduced background.
Cat B 680 FAST is a Cathepsin B activatable agent that is optically silent upon injection and produces fluorescent signal after cleavage by Cathepsin B produced by inflammatory cells and tumor cells. Cat B 680 FAST may be used to monitor inflammation, tumor activity, progression of disease and the efficacy of therapeutic treatment in applications such as oncology, inflammation, cardiovascular disease and some neurological diseases.
|
|
|
Enzyme Panel Cat B 680 FAST Cat B 680 FAST: 0.5 µM final concentration of agent in the optimized buffer for each enzyme and 0.05 µM final concentration of activated enzyme |
Longitudinal imaging of a single mouse (with a larger (left) and a smaller (right) tumor) shown at a range of time points, with identical fluorescence gating. ROI encompasses the tumor area.
Cat B 680 FAST Properties & Specifications
|
Cat B 750 FAST Characteristics
|
|
|
|
1. Absorbance and fluorescence maxima of activated Cat B 680 FAST in 1x PBS. 2. As determined by RP-HPLC and measuring |
|
Normalized absorbance (grey), excitation (blue) and fluorescence emission (red) spectra of Cat B 680 FAST in 1x PBS. |
Material (Needs to be reconstituted)
Cat B 680 FAST: Each vial contains 24 nmol of Cat B 680 FAST in dry solid form. Cat B 680 FAST has been filtered through a 0.2 µm filter prior to drying. Reconstitute Cat B 680 FAST with 1.2 mL of 1 x PBS before injecting into animals. The packaged material provides sufficient reagent for imaging approximately 10 mice (weighing ~25 grams each) when using the recommended dose of 2 nmols (100 µL) of Cat B 680 FAST per mouse. Some applications like Atherosclerosis imaging require a higher dose.
Properties
The physical characteristics of Cat B 680 FAST can be found in table above.
Storage and Handling
Upon receipt, Cat B 680 FAST should be STORED AT 2-8 oC AND PROTECTED FROM LIGHT.
When stored and handled properly, Cat B 680 FAST is stable for up to 3 months in dry solid form.
Before opening the vial check to ensure that all of the solid material is at the bottom of the vial.
After reconstituting with PBS, gently swirl the solution to ensure that the solid is fully in solution.
Once reconstituted with 1 x PBS, the solution is stable up to 10 days when stored at 2-8 ºC and protected from light.
Cathepsin B is a cysteine protease involved in the degradation of the extracellular matrix and may be one of the key factors in cancer progression. Cathepsin B correlates with invasiveness and metastatic capabilities in many tumors. In breast cancer specifically, high expression levels of cathepsin B have been linked to highly aggressive tumors and poor clinical outcome. Cathepsin B is also upregulated in a variety of inflammatory cells (including eosinophils, neutrophils, and macrophages), and may provide an inflammation readout that indicates the potential vulnerability of Atherosclerotic plaques in Cardiovascular disease.
The generally recommended procedure for in vivo imaging with Cat B 680 FAST is administration via intravenous injection and imaging 6-24 hours post injection. Earlier and later timepoints may be appropriate for some disease models, and the optimal imaging timepoint for any application should be determined empirically. Some applications like imaging of atherosclerotic plaques may require a 4 nmol dose and may benefit from a later imaging timepoint.
Cat B 680 FAST enables imaging of Cathepsin B activity in applications including:
Cardiovascular disease,
Oncology,
Inflammation,
Certain neurological diseases
|
Part #
|
|
Agent Description
|
|
|
11112 |
|
Cat B 680 FAST including 1 vial, 10 doses (based on a 20-25 g mouse)- Fluorescence agent specifically activated by cathepsin B proteinases (Cat B). Optically silent in the unactivated state, becoming highly fluorescent when activated. |
|
|